An improved understanding of the biological processes that drive neuromyelitis optica spectrum disorder (NMOSD) has led to treatment advancements in recent years. In a presentation at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2021, Sean Pittock, MD, director of the Mayo Clinic’s Center for…
Uplizna
Horizon Therapeutics is growing its rare disease portfolio by acquiring the biotechnology company Viela Bio, including the approved medicine Uplizna for treating neuromyelitis optica spectrum disorder (NMOSD). “This acquisition represents a significant step forward in advancing our strategy — to expand our pipeline,” Tim Walbert, chairman,…
Recent Posts
- Pure oxygen therapy may reduce inflammation in NMOSD: Study
- How NMOSD has quietly shaped my experience of pain
- Global study finds genetic signature in blood that identifies NMOSD
- Suddenly, seemingly out of nowhere, I found a sense of empowerment
- Soliris reduces relapse rates in AQP4-positive NMOSD patients: Study